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Abstract
Surfactant protein A (SP-A) has been shown to bind to and regulate the functions of both alveolar type II cells and
immune cells including alveolar macrophages. The interaction of SP-A with type II cells has been shown in vitro to inhibit
lipid secretion and to promote the uptake of lipid by these cells and these observations led to the hypothesis that SP-A plays
an important role in regulating surfactant turnover and metabolism. The finding that mice made deficient in SP-A by
homologous recombination (SP-A 3/3 mice) have relatively normal surfactant pool sizes has raised the possibility that
either redundant mechanisms function in vivo to keep pool sizes normal in the absence of SP-A or that the in vitro findings
are not significant in the context of the whole, unstressed animal. The interaction of SP-A with immune cells has been shown
to affect a variety of responses which, in general, function to promote host defense against infection. Although SP-A
receptors have been identified, additional studies will be required to elucidate the mechanism of interaction of SP-A with
these cells and the relative importance of the different receptors in SP-A mediated regulation of cell function. ß 1998
Elsevier Science B.V. All rights reserved.
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1. Introduction
Surfactant protein (SP) A was initially identi¢ed in
surfactant puri¢ed from lavage £uid by King and
Clements [1^3]. Although SP-A is only one of four
surfactant-associated proteins identi¢ed thus far, in
retrospect it is easy to understand why it was identi-
¢ed ¢rst. It is a very abundant protein and, unlike
the hydrophobic proteins SP-B and SP-C, it resolves
and stains easily on SDS-PAGE gels.
Because SP-A co-isolates with surfactant lipids, its
extracellular functions in mediating surface tension
reducing properties and participation in the organi-
zation of surfactant lipids were the focus of early
investigations. These concepts are discussed in other
chapters (see chapters by Goerke and McCormack in
this issue for details). The concept that SP-A may
interact with cells and regulate cell responses is a
newer one about which less is known.
The purpose of this chapter is to review the avail-
able information on the interaction of SP-A with
epithelial and phagocytic cells and the functional
consequences of those interactions. The chapter will
begin, however, with a brief discussion of the cellular
sites and sources of action of SP-A and a review of
the methods and some problems associated with pu-
ri¢cation of SP-A.
2. Cellular sources and sites of action of SP-A
Both protein and message for SP-A have been lo-
calized to the alveolar epithelial type II cell and the
Clara cell of the bronchiolar region [4,5]. Therefore,
it seems likely that SP-A secreted by these cells
would be available to interact with cells of both al-
veolar origin and bronchiolar origin. Although mac-
rophages have been shown to contain immunoreac-
tive protein [4,6], they do not contain mRNA for SP-
A. These data suggest that macrophages do not syn-
thesize or secrete SP-A and, as discussed below, it
appears that macrophages actively internalize and
degrade SP-A.
3. Puri¢cation and properties of isolated and labeled
SP-A
Many of the studies reported here were conducted
with SP-A puri¢ed by di¡erent methodologies and it
is important to note that there is clear evidence that
the method of puri¢cation can have profound e¡ects
on the functions of SP-A.
One of the most common methods of puri¢cation
is butanol extraction followed by detergent solubili-
zation or column chromatography (e.g. [7]). This bu-
tanol extraction appears to have adverse e¡ects on
SP-A isolated from some species, such as rats and
dogs, but SP-A isolated from the lavage of patients
with alveolar proteinosis, a disease of unknown eti-
ology that is characterized by an accumulation of
surfactant, seems resistant to denaturation by buta-
nol [8]. Alternative methods of SP-A puri¢cation in-
clude extraction of surfactant by chelation of calcium
[9], ion exchange chromatography [8], and treatment
of surfactant with reducing and denaturing agents
followed by isoelectric focusing [10]. Although an
exhaustive comparison of the e¡ects of SP-A isolated
by these various methods has not been reported, a
comparison of the functions of SP-A isolated from
rat and canine lavage by butanol extraction and ion
exchange chromatography indicated that there are
signi¢cant di¡erences in these preparations. These
studies raise a cautionary £ag that SP-A isolated
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by various methods may have di¡erent or altered
functions.
Another important consideration is that SP-A has
been shown to bind to bacteria and to endotoxin, a
lipopolysaccharide (LPS) that is a major component
of the bacterial cell wall. In addition, some prepara-
tions of isolated SP-A (and other surfactant proteins)
contain signi¢cant amounts of endotoxin. Since LPS
can have profound e¡ects on immune cells, it is im-
portant to measure endotoxin levels in SP-A prepa-
rations and to treat them to remove endotoxin if
necessary.
In order to characterize the binding of a ligand
(e.g. SP-A) to a population of cells, it is necessary
to label the protein in some manner. Most studies
have been carried out with radioiodinated SP-A.
However, it has been shown that iodination can af-
fect SP-A structure and function. Stuart et al. [11]
reported that oxidation of SP-A (via radioiodination
and exposure to H2O2) resulted in alterations in the
sedimentation coe⁄cient and Stokes radius values
after 10 days of storage, suggesting that the SP-A
had depolymerized. This breakdown was accompa-
nied by a decrease in carbohydrate binding activity.
Although the iodinated SP-A used in some studies
described below was characterized with respect to
retention of speci¢c functions, the observation of
Stuart and co-workers raises an important warning
that highly oligomerized proteins such as SP-A (and
SP-D) may be unstable when modi¢ed and that
this instability may become more apparent with
time.
4. Interaction of SP-A with epithelial cells
The idea that SP-A may interact with type II cells
was probably primarily derived from studies of sur-
factant metabolism, a subject addressed in detail in
the chapter by Ikegami and Jobe in this issue.
Although many studies have contributed to our over-
all understanding of surfactant clearance, a seminal
study by Hallman and co-workers [12] demonstrated
that type II cells, which synthesize and secrete sur-
factant, are also capable of internalizing surfactant
from the alveolar space. This observation raised the
possibility that the type II cell may be involved in
surfactant clearance. Several laboratories have at-
tempted to identify the factors that might regulate
this uptake pathway.
Subsequent studies using subfractions of surfac-
tant isolated by di¡erential centrifugation and en-
riched in speci¢c surfactant components showed
that subfractions enriched in SP-A were taken up
into type II cells to a greater extent than were sub-
fractions de¢cient in SP-A [13]. These studies, and
others discussed in detail below, led to investigations
of the possibility that SP-A is involved in regulating
surfactant clearance by type II cells and to studies
characterizing the binding of SP-A to type II cells.
4.1. Binding of SP-A to type II cells
Kuroki and co-workers ¢rst reported that SP-A
binds to high-a⁄nity receptors on isolated alveolar
type II cells [14]. The type II cells used in this study
were maintained in primary culture for approx. 20 h.
Hill plots of the binding data yielded an estimated
dissociation constant of 1.02 Wg/ml (or 0.64 nM).
This constant was calculated based on the assump-
tion that the native molecular mass of the oligomer-
ized form of SP-A is 1.6 MDa. Maximal binding in
this study occurred at approx. 5 Wg/ml. The binding
was calcium-dependent and was not inhibited by
treatment of type II cells with proteases including
trypsin, pronase, chymotrypsin, pepsin and papain.
Thus, it was suggested that the binding site was ei-
ther not a protein or was a protein that was highly
resistant to protease digestion. The number of cell
surface binding sites was estimated to be 135 000 sites
per cell. A comparison between binding to type II
cells and other cells showed that macrophages and
type II cells exhibited speci¢c binding whereas adult
rat lung ¢broblasts and L2 cells, a cell line derived
from alveolar epithelial cells, did not. The binding of
SP-A to macrophages will be discussed in more detail
below.
SP-A was also reported to bind with high a⁄nity
to freshly isolated type II cells [15]. Interestingly, the
properties of binding to freshly isolated type II cells
were both similar and di¡erent from the properties of
binding to primary cultures of type II cells. For
example, the number of binding sites on freshly
isolated type II cells was estimated to be 40 000 sites
per cell and half-maximal binding occurred at 5U
10310 M, assuming an oligomeric size of 650 000.
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Maximal binding occurred at approx. 1 Wg/ml. Using
the estimated oligomeric size reported by Kuroki et
al. of 1.6 MDa, then the calculated half-maximal
binding occurred at approx. 2U10310 M (0.2 nM),
a value approx. 3-fold smaller than that reported by
Kuroki et al. (The di¡erent estimates of oligomeric
size of SP-A are likely due to technical di¡erences in
the methods used for size exclusion chromatogra-
phy.) Surprisingly, treatment of freshly isolated cells
with trypsin decreased the level of binding by ap-
prox. 50%, raising the possibility that the mechanism
of binding to freshly isolated type II cells may be
occurring partly via binding of SP-A to a protease-
sensitive protein, whereas the binding to primarily
cultures of type II cells may be via a non-protein
mediated mechanism (e.g., a glycolipid, as suggested
by Kuroki et al.) or via a protease-resistant protein.
Binding to both freshly isolated cells and primarily
cultures of cells required calcium.
An important study by Ryan et al. [16] reported
that SP-A labeled with biotin binds to cultured al-
veolar type II cells in a saturable manner. Maximal
binding was obtained at approx. 10 ng/ml. The rea-
sons for the di¡erences in maximal binding reported
in this study and the study by Kuroki et al. and
Wright et al. are not known but could be related
to the vastly di¡erent methodologies used. Both Kur-
oki et al. and Wright et al. used radiolabeled SP-A
and biochemical analysis of binding. Ryan and co-
workers employed biotinylated SP-A and electron
microscopic analysis. It is possible that the di¡erent
labeling techniques may alter SP-A’s ability to bind
to type II cells. In any case, it is important to note
that this study demonstrated that SP-A was internal-
ized via a coated pit pathway by type II cells (dis-
cussed in detail below); this ¢nding provides strong
morphological support for the existence of a receptor
that participates in endocytosis of SP-A.
There are important di¡erences observed between
the binding of SP-A to freshly isolated type II cells
and cells that have been maintained in primary cul-
ture. Potential explanations for the di¡erences in af-
¢nity and receptor number observed with the freshly
isolated and cultured type II cells include the fact
that the receptor numbers and properties may
change with time in culture. In addition, some of
the observed binding, especially in the freshly iso-
lated cells, may be attributed to contaminating cells
such as macrophages. Alternatively, the receptors
may be di¡erentially clustered when cells are adhered
to tissue culture plastic. The possibility that culture
conditions may a¡ect binding is supported by the
observation by Bates et al. [17] that binding of
SP-A to isolated type II cells cultured on micropo-
rous membranes is much higher than binding to cells
cultured on plastic. In addition, it is possible that
receptors are damaged during the elastase treatment
of the lung tissue as part of the puri¢cation proce-
dure, and that the receptors recover during time in
culture. In any case, the studies, both in vivo and in
vitro, are consistent with the fact that type II cells
express receptors for SP-A.
Relatively little is known about factors that regu-
late the expression of receptors for SP-A on type II
cells. An interesting study by Chen et al. showed that
treatment of type II cells with surfactant secreta-
gogues increased receptor number [18]. In this study,
the binding of 125I-labeled SP-A was increased by
1.5^2-fold by exposure of isolated type II cells cul-
tured on Transwell membranes to the surfactant sec-
retagogues 8-bromo-cyclic AMP, phorbol 12-myris-
tate 13-acetate, terbutaline, or ATP. It is important
to note that the e¡ect was dependent upon the sub-
strate on which the type II cells were cultured, since
cells cultured on plastic did not respond to secreta-
gogues with increased binding of SP-A. Both baseline
and secretagogue enhanced binding of SP-A to type
II cells were sensitive to trypsin. These studies are
consistent with the possibility that there is a link
between surfactant secretion and clearance.
4.2. Receptors for SP-A on type II cells
The ¢ndings that SP-A binds to type II cells with
high a⁄nity and that the interaction has properties
of receptor mediated binding have led many to at-
tempt to identify the SP-A receptor on type II cells.
Several potential SP-A receptors have been identi-
¢ed. The receptors will be described in this section
and their potential involvement in SP-A mediated
type II cell function will be addressed in the subse-
quent section.
Strayer and co-workers developed anti-idiotypic
antibodies to identify a 30 kDa protein that is found
on type II cells and ciliated cells of the conducting
airways but not on alveolar macrophages [19]. This
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antibody, which was directed against the SP-A bind-
ing region of anti-SP-A antibodies was used to clone
distinct cDNAs from human and porcine cDNA ex-
pression libraries. These SP-A binding proteins were
named SPAR, an acronym for SP-A Recognition
proteins. The deduced amino acid sequences of the
human and porcine SPARs were 41% similar. The
proteins were reported to be similar to known cell
membrane receptors including the acetylcholine,
K-2C adrenergic, ryanodine, and progesterone recep-
tors. Message was detected primarily in the lung but
also in the heart, kidney and small intestine. In a
subsequent study, [20] it was shown that both anti-
bodies inhibited the binding of radiolabeled SP-A to
isolated type II cells.
Using an auto-anti-idiotypic antibody approach,
Stevens et al. identi¢ed an SP-A binding protein of
approx. 170^200 kDa under non-reducing conditions
[21]. This protein appears to be comprised of 55 kDa
subunits when analyzed under reducing and denatur-
ing conditions on SDS-PAGE gel and has been
named BP55. Antibodies against BP55 were shown
to bind to type II cell surface proteins and to inhibit
binding of SP-A to freshly isolated type II cells.
Cross-linking studies suggested that BP55 is a major
type II cell surface binding protein.
Chroneos and co-workers [22] have puri¢ed an
SP-A binding protein that is apparently di¡erent
than the proteins identi¢ed as BP55 and SPAR.
The receptor was identi¢ed on ligand blot analysis
and was detected on alveolar type II cells and macro-
phages as well as on U937 cells. Based on its size of
210 kDa, it has been called SPR210 (surfactant pro-
tein receptor 210).
An intriguing study by Momoeda and co-workers
[23] suggested that neutral glycosphingolipids may
serve as receptors for SP-A in the developing epithe-
lium of the murine lung. These investigators reported
that there were signi¢cant changes in the glycosphin-
golipid composition of murine lung in the post-natal
period. SP-A was found to bind to a variety of gly-
colipids, consistent with previous reports [24,25].
Although the functions of these glycolipids as dis-
tinct receptors and their precise localization on the
epithelium were not established, these studies are
consistent with the intriguing possibility that the re-
ceptors for SP-A may be glycolipids as well as pro-
teins.
4.3. Mechanism of binding of SP-A to isolated type II
cells
Because SP-A is a multi-domain molecule it has
been tempting to speculate that speci¢c domains of
SP-A may mediate speci¢c functions. The domain
structure is reviewed in the chapter by McCormack
in this issue and in [26]. Brie£y, the shortest domain
is the N-terminal domain, which is followed by a
longer collagen-like domain. This collagen-like do-
main is characterized by a repeating tripeptide unit
typical of collagen-like proteins containing a glycine-
X-Y, where X is any amino acid and Y is often a
hydroxylated proline. The collagen-like domain is
followed by a triple helical coiled-coil neck domain
and a C-type lectin domain. The C-type lectin do-
main is characterized by a conserved sequence of
amino acids that confer calcium-dependent carbohy-
drate binding (lectin) activity. This domain has been
abbreviated the CRD or carbohydrate recognition
domain.
Several approaches have been used to attempt to
identify the domains mediating SP-A binding to type
II cells. One approach has been to produce fragments
of SP-A, such as the collagenase-resistant fragment
or CRF. This fragment can be produced by enzy-
matic digestion of SP-A with collagenase. The result-
ing fragment is the C-terminal C-type lectin domain.
This fragment retains the ability to bind carbohy-
drates, but seems to be unstable and to have a lower
a⁄nity for carbohydrates than does the intact pro-
tein. One limitation of this approach is that it has
not been possible, thus far, to produce enzymatically
a collagen-like fragment of SP-A or a fragment of
the neck domain. Although others have successfully
digested collagen-like proteins such as C1q with pep-
sin and derived a fragment of the collagen domain,
nothing detectable by SDS-PAGE is recovered after
digestion of SP-A with pepsin.
In order to determine whether the lectin-like do-
main of SP-A mediates binding, a collagenase-resist-
ant fragment of SP-A was isolated and found to bind
to a much greater extent to type II cells than to
alveolar macrophages or ¢broblasts [15]. Murata
and co-workers [27] also showed that a collagenase-
resistant fragment of SP-A competed for binding of
intact SP-A and that the isolated fragment bound to
type II cells in a concentration-dependent manner.
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Thorkelsson and co-workers [28] used microscopic
techniques to show that the lectin activity associated
with SP-A is not required for, but may participate in
SP-A binding to rat alveolar type II cells. In this
study, it was shown that SP-A bound to horseradish
peroxidase, a mannosylated protein, but that horse-
radish peroxidase did not alter the binding of SP-A
to the type II cell surface. Thus, these data suggest
that either the carbohydrate recognition domain of
SP-A is not involved in binding, or that horseradish
peroxidase is not an e¡ective competitive inhibitor.
Kuroki and co-workers [29] reported that speci¢c
chemical modi¢cations of SP-A a¡ected its ability to
bind to type II cells. For example, SP-A that was
alkylated with iodoacetamide or reductively methyl-
ated did not compete with wild type SP-A for cell
surface binding. In addition, neither mannose nor
K-methylmannoside inhibited binding of SP-A to
type II cells. Although one interpretation of this lat-
ter ¢nding is that the lectin activity of SP-A is not
involved in binding, it is also possible that the type II
cell binding site is a carbohydrate that has a higher
a⁄nity for SP-A than does mannose or K-methyl-
mannoside.
The concept that the CRD domain of SP-A is
involved in type II cell binding is supported by re-
sults from a variety of methods. For example, Kur-
oki and co-workers have used monoclonal antibodies
against SP-A to map functional domains. Two
monoclonal antibodies (1D6 and 6E3) reduced the
high a⁄nity binding of SP-A to type II cells
[29,30]. The monoclonal 1D6 bound to an epitope
in the region of a small disul¢de loop of the CRD
(Cys-204 to Cys-218) [30]. Murata et al. [27] also
used monoclonal anti-SP-A antibodies to help de¢ne
the type II cell binding domain. One anti-SP-A
monoclonal antibody (PE10) decreased the binding
of SP-A to type II cells. Subsequent studies by
Hiraike and co-workers [31] used the same antibody
and epitope mapping to localize the region of SP-A
responsible for these activities to a region in the
CRD from Glu-202 to Met-207. Thus the epitope
mapping studies are consistent with the CRD as
the type II cell binding domain.
McCormack and co-workers employed site-di-
rected mutagenesis to produce glycosylation de¢cient
mutants of recombinant SP-A. They found that gly-
cosylation of SP-A is not required for type II cell
binding [32]. Interestingly, the carbohydrates of SP-
A are involved in binding to viruses and bacteria [33]
and mycobacterium [34,35]. These observations sup-
port the notion that di¡erent domains of SP-A may
be involved in binding to type II cell and pathogens.
Site-directed mutagenesis has also been used to
more precisely identify the receptor binding domain.
The rationale behind this approach was to use infor-
mation from the crystal structure of the homologous
mannose binding protein to predict which amino
acids might be involved in the binding to carbohy-
drates. It was shown that mutants of recombinant rat
SP-A in which Glu at position 195 was changed to
Gln and Arg at position 197 was changed to Asp
resulted in conversion of SP-A from a mannose bind-
ing lectin to a galactose binding lectin and reduced
the a⁄nity of binding to isolated type II cells [36].
Thus, these data are also consistent with the CRD as
the type II cell binding domain.
McCormack and co-workers used alanine-scan-
ning mutagenesis to replace CRD residues Glu-195,
Glu-202, Asn-214 and Asp-215 with alanine and ex-
pressed the mutant SP-A in insect cells [37]. The
N214A mutant (e.g. Asn-214 replaced with Ala)
bound and aggregated lipids, but these activities
were reduced in the mutants E195A, E202A, and
D215A. The mutant recombinant proteins did not
compete e¡ectively for binding of 125I-labeled rat
SP-A to type II cells. This study provides additional
evidence that these residues in the CRD domain are
important in SP-A interactions with type II cells.
Additional site-directed mutagenesis studies by
McCormack et al. [38] investigated the role of the
Cys residue at position 6 in forming intermolecular
disul¢de bonds and in the interactions of SP-A with
type II cells and lipids. The Cys at position 6 was
mutated to Ser to prevent disul¢de bond formation.
The Cys-6 mutant (C6S), which contained the colla-
gen-like domain but did not form appropriate disul-
¢de bonds, competed only weakly for receptor occu-
pancy. This ¢nding is consistent with the possibility
that appropriate oligomerization of SP-A may be
important in receptor binding and its ability to reg-
ulate type II cell function.
An additional mutant lacking the collagen-like do-
main (abbreviated vG8-P80, e.g. deletion of the pep-
tide from the glycine at position 8 to the proline at
position 80) was expressed in insect cells using the
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recombinant baculovirus system [26]. The vG8-P80
competed only weakly for native SP-A receptor oc-
cupancy on isolated type II cells. It was concluded
that the collagen-like region is required for competi-
tion with native 125I-SP-A for receptor occupancy.
Interestingly, it has been thought that the collagen-
like domain of SP-A may be important for oligome-
rization of SP-A, but the vG8-P80 mutant remains
highly oligomeric. This mutant does not bind with
high a⁄nity to alveolar type II cells.
Another approach which has yielded very interest-
ing and sometimes surprising results is the produc-
tion of chimeric molecules of SP-A with either SP-D
or one of the serum C-type lectins, the mannose
binding protein (MBP). This approach is very ap-
pealing because this family of proteins, known as
collectins (collagen-like lectins) are highly oligomer-
ized and oligomerization may be important in their
structure and function. Therefore, the chimeric mol-
ecules may be more likely to fold and oligomerize
correctly than the fragments of such complex mole-
cules.
Using this approach, chimeras of the mannose
binding protein and SP-A were produced in which
the region of SP-A spanning Glu-195 to Phe-228 was
replaced with the MBP-A region of Glu-185 to Ala-
221 [39]. This chimera was found to bind to type II
cells. Most surprisingly, a monoclonal antibody
mapped to this region of SP-A bound to the chime-
ras, even though that region of SP-A had been re-
Fig. 1. Involvement of SP-A in surfactant metabolism via interactions with type II cells and alveolar macrophages. SP-A has e¡ects
on the metabolism of pulmonary surfactant by both type II epithelial cells and alveolar macrophages. Surfactant lipids are secreted by
type II cells via lamellar bodies; this secretion is inhibited by SP-A. Secreted surfactant is a heterogeneous mixture with many forms,
including tubular myelin and a lipid monolayer at the air-liquid interface. SP-A binds to both type II cells and alveolar macrophages
with high a⁄nity, and stimulates the uptake of lipids by both cell types. Proteins and lipids internalized by alveolar macrophages are
generally degraded. Type II cells can either degrade or recycle internalized surfactant; the recycling pathway is favored in the presence
of SP-A.
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placed with a section of the MBP. These studies fur-
ther support the concept that the conformational and
oligomeric state of these complex molecules have
profound e¡ects on their function, and that data
must be interpreted with this notion in mind.
The aggregate of the data considered together sug-
gests that the CRD domain of SP-A may mediate
binding to type II cells and that the N-terminal in-
terchain disul¢de bond and the collagen-like domain
may contribute to appropriate folding and stability
of the SP-A molecule which may be important in
receptor binding.
4.4. E¡ects of SP-A on type II cell function
SP-A has been shown to a¡ect a variety of type II
cell functions in vitro (Fig. 1). These functions in-
clude uptake of surfactant lipid, secretion of surfac-
tant lipid, and secretion of cytokines. Each of these
e¡ects will be discussed separately.
Wright et al. reported that SP-A stimulated lipid
uptake by freshly isolated type II cells [7], and this
e¡ect was dependent on temperature and cellular me-
tabolism. The lipids that were internalized in the
presence of SP-A were degraded to a much lesser
extent than were the lipids that were internalized in
the absence of SP-A. The ¢nding by Fisher and co-
workers [40^42] that SP-A inhibits phospholipase A2
raises the intriguing possibility that SP-A may regu-
late intracellular phospholipid metabolism by a¡ect-
ing degradative enzyme activity.
Bates and co-workers [17] reported that SP-A en-
hances the uptake of pulmonary surfactant by lung
type II cells cultured on microporous membranes. A
comparison of the binding of radiolabeled SP-A to
cells cultured on microporous membranes and e¡ects
of SP-A on lipid uptake indicated that both binding
and enhancement of lipid uptake were greater in cells
cultured on microporous membranes than cells cul-
tured on plastic.
The e¡ect of SP-A on lipid uptake by type II cells
was reported to be temperature-dependent and abol-
ished by ATP depletion of the cells [43]. Several ap-
proaches were used to determine whether the lipo-
somes were adhered to the cell surface or
internalized, including treatment of cells with trypsin,
washing the cells with EGTA, and back exchange
with dioleoylphosphatidylcholine. The data were
consistent with the conclusion that SP-A increases
the internalization and not just the adherence of lip-
ids to type II cells. Consistent with other studies, it
was found that lipids internalized in the absence of
SP-A were degraded to a lesser extent than were
lipids internalized in the presence of SP-A.
Tsuzuki et al. [44] also reported that SP-A enhan-
ces uptake of phosphatidylcholine by alveolar type II
cells. Internalization was demonstrated by isolating
subcellular fractions of type II cells after the internal-
ization was allowed to occur. It was reported that
phosphatidylcholine incorporated in the presence of
SP-A was largely intact, e.g. not degraded. Kuroki
and co-workers [45] also used subcellular fractiona-
tion techniques to demonstrate that SP-A enhanced
the association of liposomes with type II cell plasma
membranes 4-fold. Studies with dual labeled lipo-
somes containing dipalmitoylphosphatidylcholine
and triolein suggested that lipid transfer was not en-
hanced by SP-A, but that the major mechanism of
enhancement was via increased binding and subse-
quent internalization. Although SP-A increased the
aggregation of liposomes, the increase in aggregation
was much less than the increase in association with
cells suggesting that the mechanism of increased as-
sociation was not due solely to aggregation of lipids.
The cell speci¢city of the SP-A response was inves-
tigated by Rice and co-workers [46] who reported
that SP-A enhanced the uptake of lipids in a cell
speci¢c manner; SP-A did not enhance uptake of
PC by Chinese hamster ovary cells but did increase
uptake by isolated type II cells.
The studies described above as well as others
[30,36] have shown that SP-A enhances lipid uptake
by type II cells. In contrast, Horowitz and co-work-
ers reported that SP-A did not increase the uptake of
lipids by either isolated rat type II cells maintained in
primary culture or MLE-12 cells, a pulmonary ad-
enocarcinoma cell line with alveolar cell character-
istics [47]. The reasons for the apparent con£icts
are not known but may be related to di¡erences in
the preparations of SP-A or the culture and isolation
conditions used to obtain the cells.
SP-A has also been observed to inhibit lipid secre-
tion in vitro. SP-A inhibited lipid secretion by pri-
mary cultures of type II cells stimulated by terbuta-
line, phorbol 12-myristate 13-acetate, or the
ionophore A23187 [48]. Rice and co-workers also
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reported that SP-A inhibited phospholipid secretion
induced by phorbol ester, a L-adrenergic agonist, and
a P2-purinergic agonist. Interestingly, the presence
of phospholipid abrogated the SP-A inhibition [49,
50].
Studies from several laboratories using several dif-
ferent approaches have provided evidence that SP-A
is taken up by type II cells and incorporated into
lamellar bodies. For example, Ryan and co-workers
used electron microscopic techniques to demonstrate
that biotinylated SP-A was internalized by isolated
type II cells [16]. They observed that SP-A was clus-
tered in coated pits on the cell’s surface, internalized,
and eventually became associated with coated
vesicles, endosomes, and multivesicular bodies. In
vivo studies by Young and co-workers, using both
biochemical techniques and electron microscopic
autoradiography, extended these studies to the whole
animal and showed that SP-A is taken up in the
intact lung and incorporated into lamellar bodies
[51,52]. An apparently con£icting study by Kalina
and co-workers showed that gold labeled SP-A was
internalized by type II cells but not incorporated into
lamellar bodies [53]. Young and co-workers have re-
ported that the method of labeling SP-A may a¡ect
its ability to be internalized (Young, personal com-
munication).
Although the in vitro work is compelling, recent
studies using mice in which the SP-A gene has been
ablated by homologous recombination (SP-A (3/3)
mice), show that these mice have moderately altered
surfactant pool sizes, in spite of a complete lack of
SP-A [54]. For example, the alveolar saturated phos-
phatidylcholine pools were 50% larger and the lung
tissue saturated phosphatidylcholine pools were 26%
larger in SP-A (3/3) mice than in wild type (SP-A
(+/+)) mice. The synthesis of new PC, measured by
following incorporation of radiolabeled choline and
palmitate into lung tissue PC, was similar for SP-A
(3/3) mice and SP-A (+/+) mice [55]. In addition,
the secretion of the radiolabeled PC was similar in
control and knock-out mice. Interestingly, the SP-A
(3/3) mice retained more labeled PC in the lungs at
48 h, a ¢nding consistent with observation that the
pool size is increased. The authors concluded that,
overall, the absence of SP-A had minimal e¡ects on
the metabolism of PC.
How can these studies with SP-A knock-out mice
be reconciled with the in vitro work? It is, of course,
possible that the in vitro work is artifactual. It is also
possible, however, that compensatory mechanisms
may function in the absence of SP-A and result in
adjustments that obscure evidence of a large direct
e¡ect of SP-A on lipid metabolism. This possibility
seems reasonable in light of the studies that have
shown that many animals in which genes have been
ablated have no obvious phenotype, possibly due to
redundant compensatory mechanisms [56^58]. In ad-
dition, it seems possible that when the SP-A de¢cient
animals are stressed, e.g. by exercise, an acute in£am-
mation, lung injury or infection, the regulatory role
of SP-A may become more evident. Further investi-
gations to elucidate the role of SP-A in regulating
surfactant metabolism are important.
The same approaches that have been used to map
type II cell binding domains have been employed to
determine which domain is involved in SP-A regula-
tion of type II cell function. For example, Kuroki et
al. [29,30] observed that two monoclonal antibodies
(1D6 and 7E3) blocked ability of SP-A to inhibit
phospholipid secretion. The monoclonal antibody
6E3, which binds the neck region of SP-A, blocked
lipid uptake into type II cells but not lipid aggrega-
tion or lipid binding. Another monoclonal antibody,
1D6 which binds the CRD, blocked the interaction
of SP-A with phospholipid and the ability of SP-A to
increase lipid uptake [30]. Thus, these studies support
the concept that the CRD may be involved in regu-
lating type II cell function.
SP-A in which Glu-195 was changed to Gln-195
and Arg-197 was changed to Asp-197 by site-directed
mutagenesis had a decreased ability to inhibit phos-
pholipid secretion [36]. A recombinant SP-A lacking
the collagen-like domain was a potent inhibitor of
surfactant secretion, in spite of the fact that it did
not compete with wild type SP-A for receptor occu-
pancy. This deletion mutant also enhanced lipid up-
take by type II cells [26]. In contrast, the SP-A mu-
tant lacking Cys-6 only weakly inhibited surfactant
secretion. Neither C6S nor vG8-P80 mutants en-
hanced lipid association with type II cells [38]. The
mutants in which alanine-scanning mutagenesis was
used to replace Glu-195, Glu-202, Asn-214 and Asp-
215 with alanine were much less e¡ective at regulat-
ing surfactant secretion and uptake by type II cells
[37]. The mutants E195Q and R197D were no longer
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able to enhance lipid uptake by type II cells. These
data are consistent with the possibility that SP-A
interactions with type II cells and regulation of
type II cell function is complex.
The oligomeric state of the SP-A molecule also has
e¡ects on its function. For example, Hattori and co-
workers reported that oligomerized SP-A isolated
from lavage of patients with alveolar proteinosis
had a reduced ability to inhibit phospholipid secre-
tion and had a lower a⁄nity for binding to type II
cells [59].
Several studies have also attempted to identify
which receptor is involved in SP-A mediated e¡ects
on lipid metabolism. An auto-anti-idiotypic antibody
against BP55, a type II cell surface protein that binds
SP-A, inhibited the SP-A mediated enhancement of
lipid uptake, and it was suggested that BP55 may be
the receptor responsible for the SP-A mediated en-
hancement of lipid uptake [43]. Interestingly, this
antibody did not decrease the ability of SP-A to in-
hibit phospholipid secretion, suggesting that di¡erent
receptors may mediate these functions of SP-A.
Two antibodies against the 30 kDa SPAR protein
were shown to modulate the SP-A mediated inhibi-
tion of phospholipid secretion by SP-A [20]. Both
antibodies inhibited SP-A’s e¡ect on secretion of
phospholipid stimulated by any of several surfactant
secretagogues, including ATP, dibutyryl cAMP,
terbutaline, and ionomycin. Taken together these
studies suggest that this receptor may be involved
the SP-A mediated regulation of phospholipid secre-
tion.
The 210 kDa receptor identi¢ed by Chroneos and
co-workers may also be involved in regulating the
e¡ects of SP-A on phospholipid secretion [22].
Anti-receptor polyclonal antibodies inhibited the
binding of SP-A to both type II cells and macro-
phages and reduced the SP-A mediated inhibition
of phospholipid secretion in vitro. The anti-receptor
antibodies also blocked SP-A mediated macrophage
e¡ects (discussed in detail below). Thus, it is possible
that more than one receptor (the 30 kDa protein
described by Strayer and the 210 kDa protein de-
scribed by Chroneos and co-workers) may both par-
ticipate in SP-A mediated inhibition of phospholipid
secretion. The possibility that these antibodies may
react with di¡erent subunits of the same receptor has
not been addressed.
5. Interaction of SP-A with phagocytes
SP-A has been shown to bind to a number of
phagocytic cells, with di¡erent binding characteristics
and downstream e¡ects of that binding. In examin-
ing the role of SP-A in pulmonary host defense, the
interactions of SP-A with alveolar macrophages and
peripheral blood monocytes have been well studied;
several studies have also looked at the interaction of
SP-A with other phagocytic cells, such as neutro-
phils, bone marrow-derived macrophages, mono-
cyte-derived macrophages, and various monocytic
cell culture lines. While there is some controversy
about the speci¢c receptors involved in these proc-
esses, and more controversy about the speci¢c nature
of SP-A stimulation of phagocytes, the vast majority
of studies clearly delineate a role for SP-A in the
regulation of phagocyte activity in the lung.
5.1. Binding of SP-A to phagocytic cells
Not surprisingly, the initial characterizations of
SP-A interaction with phagocytic cells looked at
binding to whole cells, in attempts to de¢ne the cell
types to which SP-A binds as well as the nature of
that binding. Initial binding studies focused mainly
on SP-A binding to type II cells, but also included
alveolar macrophages for purpose of comparison. In
1988, Kuroki and colleagues were the ¢rst to dem-
onstrate that SP-A binds with high a⁄nity to rat
alveolar macrophages using 125I-labeled rat SP-A
[14]. Shortly thereafter, Wright et al. con¢rmed these
results in another study of type II cells, showing not
only that SP-A bound in a speci¢c manner to alveo-
lar macrophages, but that this binding was calcium-
dependent and that collagen was less e¡ective in
competing for this binding than for binding to type
II cells [15].
Later studies focused speci¢cally on SP-A binding
to phagocytic cells, and began to de¢ne the mecha-
nism of SP-A binding to these cells. In three related
studies, Schlepper-Scha«fer and colleagues examined
the binding of recombinant human SP-A-coated
gold particles to human peripheral blood monocytes
and monocyte-derived macrophages [60] and of both
SP-A-coated gold and unbound SP-A to alveolar
macrophages [61,62] by electron microscopy. In the
¢rst of these studies, Wintergerst et al. found that
BBADIS 61775 30-10-98
M.J. Tino, J.R. Wright / Biochimica et Biophysica Acta 1408 (1998) 241^263250
both monocytes and monocyte-derived macrophages
bind and internalize SP-A-gold particles, and that
macrophage uptake of SP-A-gold was 2.4-fold higher
than that of monocytes. Additionally, they found
that the uptake of SP-A-gold particles occurred
through coated pits, and that this uptake was inhib-
ited in both cell types by mannosyl-BSA, but not
galactosyl-BSA [61].
These results were con¢rmed by the later studies
on alveolar macrophages; alveolar macrophages
bound and internalized more SP-A-gold particles in
less time, and mannosyl-BSA showed slightly less
inhibition of SP-A-gold binding and uptake than in
the previous study (59% inhibition with alveolar
macrophages vs. 73% inhibition with monocyte-de-
rived macrophages) [61]. Additionally, it was shown
that the interaction between SP-A-gold particles and
alveolar macrophages was speci¢c (inhibited by an
excess of uncoupled SP-A) and calcium-dependent
(inhibited in the presence of 10 mM EDTA). In a
third study, unbound SP-A was incubated with al-
veolar macrophages, which were then incubated with
anti-SP-A antiserum and protein A-coupled gold
particles [62]. The results of this study correlated
nicely with the previous two; SP-A binding to alveo-
lar macrophages was found to be calcium-dependent,
and inhibitable to some extent by mannosyl-BSA (to
a maximum inhibition of 36%, lower than in either of
the previous studies), the collagenase-resistant frag-
ment of SP-A (maximum inhibition of 44%) and the
collagen-like fragment of C1q (maximum inhibition
of 19%), indicating the possibility of two mechanisms
for SP-A binding to phagocytes, via both the collag-
enous and carbohydrate binding domains.
Other investigators used radioiodinated rat SP-A
to characterize SP-A binding to rat alveolar macro-
phages [63]. This was the ¢rst study to quantitate the
binding characteristics of SP-A to alveolar macro-
phages; in it, it was shown that SP-A binding to
alveolar macrophages is speci¢c as well as time-, tem-
perature-, and concentration-dependent, and, assum-
ing that the SP-A oligomer has a molecular mass of
1.6 MDa, has an apparent Kd of between 2 and 4 nM
[14]. Additionally, the concentration of SP-A at
which binding was half-maximal was measured to
be 4 Wg/ml. In an apparent contradiction of the re-
sults of Manz-Keinke et al. which implicated the
carbohydrate binding domain of SP-A in cell bind-
ing, Pison and colleagues found that large molar ex-
cesses of both collagen and the SP-A structural ho-
mologue complement component 1q (C1q), while less
e¡ective than unlabeled SP-A, could inhibit the bind-
ing of labeled SP-A to cells, and that heating SP-A to
50‡C decreases cell binding by 58% [63]. This heat
treatment corresponds to the thermal denaturation
temperature of the collagen-like triple helices of
SP-A [64^66]; these ¢ndings taken together were
used to support the hypothesis that the collagenous
domain of SP-A is at least partially responsible
for the interaction of SP-A with alveolar macro-
phages.
In a study designed to look at the distribution of
cell surface receptors for SP-A by comparing the
recovery of cells with SP-A-coated magnetic beads,
Oosting and Wright found that preincubation of al-
veolar macrophages with SP-A signi¢cantly inhibited
their binding to SP-A-coated beads [67]. This study
demonstrated that recovery of alveolar macrophages
with SP-A-coated beads was greater than that of any
other cell type. The other cells tested, in decreasing
order of recovery, were peritoneal macrophages, neu-
trophils, alveolar type II cells, COS cells, and, in
contrast to the results of Malhotra et al. [68], mono-
cytic U937 cells [67].
Studies of the interaction between SP-A and other
phagocytic cells are not as comprehensive as those
with alveolar macrophages. In the previously de-
scribed study by Ohmer-Schro«ck et al., no binding
of £uorescently labeled SP-A (FITC-SP-A) was de-
tected to peritoneal macrophages or liver macro-
phages (Kup¡er cells), although results of this study
were not quanti¢ed [62]. Chroneos and colleagues
found speci¢c, saturable, high-a⁄nity (Kd = 2.2 nM)
binding of SP-A to bone marrow-derived macro-
phages, which was calcium-dependent, and not inhib-
ited by either mannan or C1q [22]. In a quanti¢ed
study using FITC-SP-A, Geertsma et al. examined
the binding of SP-A to peripheral blood monocytes,
granulocytes, and lymphocytes, and found that while
FITC-SP-A binding to monocytes was dramatically
higher than to either of the other cell types tested,
this binding was neither saturable (at concentrations
as high as 50 Wg SP-A/ml) nor blocked by excess
unlabeled SP-A; preincubation of cells with a 200-
fold molar excess of unlabeled SP-A failed to signi¢-
cantly reduce binding of FITC-SP-A to monocytes
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[69]. Interestingly, preincubation of monocytes with
C1q at molar ratios as low as 5:1 signi¢cantly re-
duced FITC-SP-A binding to them, and preincuba-
tion with a 20-fold molar excess of C1q completely
eliminated FITC-SP-A binding to the cells [69].
5.2. Cell surface receptors for SP-A on phagocytes
The studies summarized above served to support
the previously developed hypothesis that receptors
for C1q are responsible for SP-A binding to mono-
cytic cells. In a prior set of studies by Malhotra et al.,
a 115 kDa receptor for C1q (C1qR) was identi¢ed on
the monocytic cell line U937 and postulated to be
responsible for SP-A binding to those cells
[68,70,71]. The ¢rst studies examined the ability of
C1q, SP-A, MBP, conglutinin, and collagen to inhib-
it binding of 125I-labeled C1qR to C1q immobilized
on microtiter plates. In two separate studies, it was
shown that conglutinin, C1q, MBP, and SP-A all
inhibit binding of C1qR to immobilized C1q
[70,71]. This inhibition was shown for C1qR:inhibi-
tor molar ratios of approx. 1:2800, 1:1400 [70] and
1:140 [71]. In a third study, Malhotra and colleagues
demonstrated speci¢c, saturable, salt-dependent,
high-a⁄nity (Kd = 0.7 nM) binding of SP-A to
U937 cells [68]. They found this binding to be com-
peted by both C1q and C1qR, supporting their hy-
pothesis that SP-A binds to C1qR on the surface of
U937 cells.
In addition to C1qR, two other proteins have been
identi¢ed that bind SP-A in di¡erent fractions of
whole lung homogenate. These proteins are SPR210
and cellular myosin. Only SPR210 has been localized
to the cell surface, and its cellular distribution is not
limited to phagocytic cells [22]. Michelis et al. re-
ported in 1994 that SP-A binds myosin, and that
this binding is concentration-dependent [72]. While
this study postulated that this interaction could
have functional importance in lung injury, further
studies led to the possibility that the coiled-coil motif
was important in SP-A binding (Michelis, unpub-
lished results). Chroneos and colleagues identi¢ed a
210 kDa cell-surface protein which binds SP-A,
SPR210 [22]. Puri¢ed on a column made by binding
SP-A to maltose-coupled sepharose beads, SPR210
likely binds the collagen-like domain of SP-A; it
was further puri¢ed from U937 cell membranes,
and found on bone marrow-derived macrophages
and type II cells [22].
5.3. Mechanism of SP-A interaction with phagocytes
Many groups of investigators have used binding
and receptor studies to draw conclusions about the
mechanism of SP-A-phagocyte interaction. These ex-
periments have been complicated and often di⁄cult
to interpret; as a result, evidence exists to support
several di¡erent hypotheses about the domain or do-
mains of SP-A involved in binding to phagocytic
cells.
The most common technique used to examine SP-
A binding is a competition assay in which the ability
of various proteins to compete for SP-A binding to
cells or to stimulate function is assessed. Those seek-
ing to examine binding to the C1q receptor have
used unlabeled C1q and iodinated SP-A to provide
evidence for their claims that SP-A binds [68] or does
not [22] bind to cells via the C1q-R. In examining
the role of the collagenous domain of SP-A in its
interactions with cells, types IV and V collagen
have also been used to block SP-A binding to cells
[15,63].
Thus far in the literature, competition assays have
proven inconclusive. Assays using collagen as a com-
petitor for SP-A have yielded con£icting results. Ex-
treme excesses of collagen (an almost 300:1 molar
ratio) have been shown to block the binding of la-
beled SP-A to alveolar macrophages by 30% [15].
Other studies, however, seem to con£ict with this
data. In one report, collagen was shown to be less
e¡ective than C1q in competing for SP-A binding
and only marginally more e¡ective than BSA except
at molar ratios approaching and exceeding 1000:1,
and then only to about 40% less than control levels
[63]. While C1q has been more e¡ective in competi-
tion assays looking at binding to U937 cells [68], and
alveolar macrophages [63], another study found that
the addition of unlabeled C1q increased SP-A bind-
ing to rat bone marrow-derived macrophages by over
100% [22].
Oosting and Wright, in their study of cell recovery
assay using SP-A-coupled magnetic beads, addressed
one potential explanation for the con£icting results
in these studies: the direct interaction of SP-A with
other proteins in solution. In this study, they exam-
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ined the binding of 125I-labeled SP-A to proteins im-
mobilized on microtiter plates, and found that SP-A
binds to itself, SP-D, and C1q, a previously unre-
ported result which complicates coincubation compe-
tition experiments with either whole cells or immobi-
lized proteins [67]. In addition, this study
characterized the binding of cells to SP-A-coupled
beads after preincubation or coincubation of cells
with several potential competitors for cell binding
and in the presence of carbohydrates and carbohy-
drate-bound BSA. Speci¢cally, the study found that
coincubation of cells with SP-A-coated beads and
SP-A, SP-D, C1q, mannosyl-BSA, or heat-treated
or deglycosylated SP-A signi¢cantly reduced alveolar
macrophage recovery. Interestingly, it was also found
that only preincubation of the cells with SP-A (un-
treated, deglycosylated, and heat-treated SP-A all
were e¡ective) reduced alveolar macrophage recov-
ery; pre- or coincubation with collagenase-treated
SP-A, mannose binding protein, type V collagen,
mannan, or fucoidin did not [67]. These data, taken
together, support the hypothesis that SP-A binding
to alveolar macrophages is at least partially due to
the collagen-like domain of SP-A, and that it is in-
dependent of SP-D, C1q, and MBP binding.
Several studies support a model of SP-A-phago-
cyte interaction via the other domains of SP-A.
Some studies have argued that the interaction of
SP-A with cells involves the carbohydrate binding
domains of SP-A. These studies have shown that
SP-A binding to monocyte-derived macrophages
can be inhibited by the addition of mannosyl-BSA
[60,61]. In another study, it was shown that the col-
lagenase-resistant fragment of SP-A binds non-spe-
ci¢cally to alveolar macrophages [15]. Furthermore,
the binding of SP-A to cells has been shown by many
groups to be calcium-dependent [15,67] suggesting
that the structure of the collagenase-resistant portion
of SP-A is vital to cell binding. It is possible, how-
ever, that a calcium-dependent conformational
change, independent of the calcium-dependent lectin
activity of SP-A, is important for SP-A binding to
cells.
5.4. Functional consequences of SP-A binding to
phagocytes
In order to examine further the mechanism of
SP-A binding to phagocytes, it became necessary to
de¢ne the functional consequences of that binding.
Almost all recent studies seeking to characterize the
interaction of SP-A with various cell types have re-
lied on functional assays to draw their conclusions. A
variety of techniques, from competition to receptor
clustering assays, have been used to examine both
the domains of SP-A responsible for cell binding
and the cell surface proteins responsible for function-
al interactions.
Alveolar macrophages are the predominant cell
type within the alveolus, and are responsible for
the ¢rst line of pulmonary host defense [73]. There-
fore, most studies that sought to characterize func-
tional interactions with phagocytes have focused on
alveolar macrophages. Because alveolar macrophages
do not divide in culture, they must be taken directly
from lung lavage; this isolation method has caused
some investigators to look elsewhere for the targets
of functional studies: peripheral blood monocytes,
monocyte-derived macrophages, and bone marrow-
derived macrophages are the most common other
cells used in these assays, with limited success.
Some recent research has also been done on neutro-
phils, the second most common cell type in lung
lavage, and an important part of the phagocytic re-
sponse to some infections.
Functional studies involving SP-A and phagocytes
can be divided into several categories. The large ma-
jority of these studies have focused on the relation-
ship between SP-A and the uptake and/or phagocy-
tosis of pathogens, foreign particles, and surfactant
lipids; other studies have looked at intracellular sig-
naling pathways stimulated by SP-A, the stimulation
of cellular responses such as actin polymerization
and chemotaxis, and the regulation of cytokine and
reactive species production and secretion. The inter-
action of these processes forms the basis of a model
for SP-A involvement in pulmonary host defense
(Fig. 2).
5.5. Non-phagocytic cellular responses to SP-A
Binding studies to whole cells are consistent with
the existence of at least one cell surface receptor for
SP-A; functional data support this, and, in fact, a
tenable hypothesis is that numerous SP-A binding
receptors exist with di¡erent functions. The ¢rst con-
BBADIS 61775 30-10-98
M.J. Tino, J.R. Wright / Biochimica et Biophysica Acta 1408 (1998) 241^263 253
sequence of receptor binding is the transmission of
intracellular signals; certain signaling pathways are
common motifs, and various groups have examined
the signaling pathways activated by SP-A in phago-
cytes.
SP-A increases intracellular calcium and inositol
triphosphate (IP3) concentrations in alveolar macro-
phages. In two separately reported studies by
Ohmer-Schro«ck and colleagues, it was reported that
SP-A stimulates an increase in intracellular calcium
concentration, as measured by the increase in £uo-
rescence of fura-2, a calcium indicating dye [62]. In
their initial study, they found that the free cytosolic
calcium concentration in adherent alveolar macro-
phages increased immediately after the addition of
SP-A to a ¢nal concentration of 60 Wg SP-A/ml,
and that the increase reached a plateau more than
2 min after stimulation [62]. These ¢ndings were cor-
roborated by the later study, which also found that
this stimulation is concentration-dependent in that
increased SP-A concentrations lead to a higher per-
centage of responding cells, and that the calcium
response correlates with an increase in the generation
of IP3, an active intracellular signaling molecule [74].
This study also reported that the increase in calcium
was necessary for SP-A stimulated phagocytosis, a
¢nding that correlates with ¢ndings on IgG-mediated
phagocytosis [75].
Another common signaling pathway in phagocytes
is the activation of tyrosine kinases, which regulate
protein activity by phosphorylating tyrosine residues
on them. In a study presented in an abstract, we have
shown that SP-A stimulates protein tyrosine phos-
phorylation in alveolar macrophages, but not in pe-
ripheral blood monocytes or peritoneal macrophages
[76]. In a related study, it was demonstrated that
both tyrosine phosphorylation and actin polymeriza-
tion are also necessary for SP-A-stimulated phagocy-
tosis [77].
Receptor binding and subsequent downstream sig-
nals are also necessary for the directed rearrange-
ment of the actin cytoskeleton, a process tightly con-
trolled in motile phagocytic cells (reviewed in [78]).
Studies characterizing actin polymerization and mo-
tility in alveolar macrophages have revealed not only
that SP-A stimulates alveolar macrophage chemo-
Fig. 2. Model for SP-A involvement in pulmonary host defense. The interaction of SP-A with alveolar macrophages leads to the regu-
lation of many of the host defense properties of the macrophage. SP-A binding to cell surface receptors triggers the transduction of
speci¢c intracellular signalling cascades, including the tyrosine phosphorylation of proteins (shown), the release of intracellular calci-
um, and the production of inositol triphosphate, an active signaling molecule. These signals have many e¡ects on cellular processes.
SP-A has been shown to stimulate the directed polymerization of actin micro¢laments, consistent with its role as a macrophage che-
moattractant; macrophages migrate towards higher concentrations of SP-A in vitro. SP-A has also been shown to have various e¡ects
on the expression of proteins such as iNOS, and the subsequent production of reactive species of nitrogen. SP-A also regulates the se-
cretion of reactive oxygen species and cytokines such as TNF-K, IL-1L, and IL-6 by alveolar macrophages. Finally, SP-A binds to
pathogens and stimulates their phagocytosis by alveolar macrophages; phagocytosis often leads to the inactivation and/or killing of
potentially harmful organisms.
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taxis in a concentration-dependent manner [79], but
that it also stimulates directional actin polymeriza-
tion in alveolar macrophages [80]. Comparisons with
peripheral blood monocytes have revealed that SP-A
stimulates neither function in them although SP-A
does stimulate the migration of peritoneal macro-
phages [79].
The study which established that SP-A stimulates
alveolar macrophage chemotaxis also examined the
mechanism of this stimulation. Wright and Youmans
[79] found that SP-A stimulation of alveolar macro-
phage chemotaxis is blocked by the addition of a 20-
fold excess of collagen, and that this stimulation is
signi¢cantly decreased after heat treatment of the SP-
A at 50‡C, a temperature which denatures the colla-
gen-like triple helices of SP-A. These ¢ndings sup-
port the hypothesis that SP-A stimulates chemotaxis
through a cell interaction involving its collagen-like
domain, although interactions involving other do-
mains were not ruled out; this hypothesis was further
supported by studies which showed that the collagen-
resistant fragment of SP-A does not stimulate che-
motaxis by itself [79].
SP-A also a¡ects the production of several impor-
tant mediators of in£ammation and immune defense,
including cytokines such as TNF-K and colony stim-
ulating factors (CSFs) as well as reactive species of
oxygen and nitrogen. The precise balance of these
cell products is essential in the lung as elsewhere;
cytokine release controls the in£ammatory response
and the proliferation and recruitment of other im-
mune cells, and reactive species can lead to tissue
damage if uncontrolled. The precise contribution of
SP-A to this balance is the matter of some contro-
versy in the ¢eld, as various groups have reported
di¡erent results using SP-A puri¢ed by di¡erent
methods.
The e¡ect of SP-A on cytokine release by alveolar
macrophages has been studied by several groups.
Blau and colleagues found that SP-A stimulates the
production of CSFs by both type II cells and alveo-
lar macrophages [81]. While the bioassay used did
not di¡erentiate between the several di¡erent types
of CSFs, the morphological characteristics of colo-
nies formed in medium conditioned by SP-A-stimu-
lated alveolar macrophages were similar to those
grown in medium with IL-3, or conditioned with
LPS- or IL-1-stimulated alveolar macrophages. Sig-
ni¢cantly, SP-A did not stimulate CSF production in
peritoneal macrophages [81].
The role of SP-A in regulating lung in£ammation
is unclear. SP-A has been reported both to stimulate
production of a host of in£ammatory cytokines, in-
cluding TNF-K, and to inhibit LPS-stimulated TNF-
K production. In studies by Kremlev and colleagues,
SP-A stimulated release of TNF-K and interleukins
1L and 6 (IL-1L and IL-6) by peripheral blood
mononuclear cells, alveolar macrophages, spleno-
cytes, [82] and monocytic cell line THP1, as well as
the cell surface expression of proin£ammatory cell
surface markers CD14, CD54, and CD11b on
THP-1 cells [83]. Investigators in this group have
also reported that SP-A activates the transcription
factor NF-UB in THP-1 cells; gel-shift assays were
used to demonstrate a stimulation of activity of this
factor, an important regulator of proin£ammatory
protein expression. Contrary to these studies are
those done by McIntosh et al., who found that SP-
A reduced TNF-K activity in medium conditioned by
LPS-stimulated alveolar macrophages, and that this
reduction was dose-dependent, serum-independent,
and reversible [84].
The major di¡erence between these studies is the
method used for the puri¢cation of SP-A. Kremlev
and colleagues use an isoelectric focusing method
after solubilization of alveolar proteinosis (AP) pro-
teins in 3 M urea, 1% 2-mercaptoethanol, and 0.1%
NP-40 [10,82,83]; the results obtained by McIntosh
et al. have been reproduced with SP-A puri¢ed by
either butanol extraction from AP lavage [84] or a
gentler, non-butanol-based EGTA extraction method
[9] (unpublished results). Recent in vivo studies using
knock-out mice may be the key to resolving this
controversy; the ¢rst reports on this subject support
the role of SP-A in attenuating lung in£ammation
[85].
SP-A has been reported by various groups to have
e¡ects on the production of reactive oxygen and ni-
trogen metabolites by phagocytic cells. These prod-
ucts are important mediators of host defense; they
are important in the killing of ingested and extracel-
lular pathogens, and they participate in both intra-
cellular and intercellular signaling pathways. While
there are signi¢cant di¡erences among the ¢ndings
of these studies, some of them appear to be explain-
able.
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In two di¡erent studies, it has been demonstrated
that SP-A stimulates the release of reactive oxygen
metabolites from alveolar macrophages [86,87]; two
studies have found that SP-A decreases PMA-stimu-
lated superoxide production in canine neutrophils
and alveolar macrophages [88] and rat alveolar mac-
rophages [89]. In the ¢rst study, van Iwaarden and
colleagues reported that human AP-derived SP-A in-
duces a lucigenin-dependent chemiluminescence re-
sponse in rat alveolar macrophages; this response,
indicative of the production of oxygen radicals, was
shown to be concentration-dependent at concentra-
tions up to 3 Wg SP-A/ml and independent of the
response generated by Staphylococcus aureus. Fur-
thermore, this stimulation was speci¢c to alveolar
macrophages, and not seen in rat peritoneal macro-
phages, rat or human neutrophils, or human periph-
eral blood monocytes [86], a ¢nding consistent with
that of Goodman and Tenner, who demonstrated
that AP SP-A coated onto plates did not stimulate
reactive oxygen production in neutrophils, although
C1q and fragments of the C1q collagen-like domain
did [90], by a mechanism later attributed to binding
via CD18 [91].
Contrasting this study is another with a similar
¢nding. Weissbach et al. [87] reported several years
later that only SP-A bound to a surface stimulates
superoxide production by alveolar macrophages,
measured in a similar fashion to van Iwaarden and
co-workers. In this study, they found that this stim-
ulation was concentration-dependent up to a coating
concentration of 80 Wg SP-A/ml, and that no en-
hancement of oxygen radical production was seen
in either alveolar macrophages stimulated with solu-
ble canine or rat SP-A or in peripheral blood mono-
cytes adhered to SP-A-coated surfaces. The authors
of this study postulated that the di¡erences between
this study and that of van Iwaarden et al. could be
explained if SP-A puri¢ed from alveolar proteinosis
patients was aggregated in such a fashion as to
mimic binding to a surface.
Supporting this claim are two studies which dem-
onstrated that soluble SP-A not only does not stim-
ulate reactive oxygen production, but decreases the
production of reactive oxygen species in PMA-
stimulated cells. In the earlier of these studies, Weber
and colleagues demonstrated that preincubation of
either canine alveolar macrophages or blood-derived
neutrophils with SP-A for 30 min signi¢cantly de-
creases their respiratory burst stimulated with
PMA, and that SP-A has no e¡ect on reactive oxy-
gen production in unstimulated cells [88]. Interest-
ingly, collagenase-treated SP-A had an opposite ef-
fect on neutrophils in this study, increasing oxygen
radical production; this ¢nding would have been
more signi¢cant had a wide variety of test proteins,
including such things as porcine lactate dehydrogen-
ase, canine alkaline phosphatase and bovine serum
albumin, not had similar e¡ects [88]. In the only
study to use a di¡erent system of superoxide meas-
urement, Katsura et al. found that rat SP-A alone
had no e¡ect on rat alveolar macrophage super-
oxide production, as measured by ferricytochrome c
reduction, and that preincubation of cells for at least
2 h with SP-A concentrations between 1 and 10 Wg/
ml decreases their oxidative response to PMA;
human AP SP-A also had a signi¢cant inhibitory
e¡ect on the PMA-stimulated response in this study
[89].
Nitric oxide (NO) is a reactive species of nitrogen
which also has a role in host defense properties of
phagocytic cells. Increases in alveolar macrophage
NO production are generally caused by induction
of nitric oxide synthase (iNOS) synthesis; these in-
creases have been obtained by many in£ammatory
stimuli. Blau and colleagues have reported that SP-
A induces expression of iNOS, with a corresponding
increase in NO production [92]. This study found
that although less e¡ective than IFN-Q or LPS in
stimulating nitrite release, both rat and human AP-
derived SP-A stimulated NO production in a concen-
tration- and time-dependent manner. In addition,
this group found that peritoneal macrophages and
type II cells were not stimulated by SP-A to produce
NO, although both cell types were stimulated by LPS
and IFN-Q.
5.6. SP-A stimulation of phagocytosis and uptake
The interaction of SP-A with phagocytic cells has
been looked at most thoroughly as a stimulus for
endocytic and/or phagocytic uptake of various par-
ticles, from endogenous surfactant lipids and pro-
teins to inhaled pollen grains [93] and pathogens.
This work has established a clear role for SP-A in
regulating both the clearance and metabolism of sur-
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factant and in stimulating non-in£ammatory host de-
fense pathways in the lung.
Initial characterizations of the functional interac-
tions of SP-A with phagocytes examined the uptake
and processing of surfactant lipids and SP-A by al-
veolar macrophages, both in vivo and in vitro (Fig.
1). Early studies showed that alveolar macrophages
had immunoreactive surfactant proteins in their sec-
ondary lysosomes, both in the presence and absence
of surfactant lipids [6]. Using exogenous surfactant
with £uorescein-labeled protein components, Stern
and colleagues con¢rmed the ¢nding that alveolar
macrophages take up surfactant proteins, also postu-
lating that this uptake occurred independently of lip-
id catabolism [94].
Later studies looked speci¢cally at the uptake of
SP-A by alveolar macrophages and the e¡ect of
SP-A on their uptake and metabolism of surfactant
lipids. An early study of DPPC uptake by alveolar
macrophages showed that SP-A (then called SP 26-
36) stimulated the uptake of 14C-DPPC-containing
liposomes by alveolar macrophages to levels almost
20-fold greater than without it ; in this study, SP-A
had no signi¢cant e¡ect on lipid uptake by ¢bro-
blasts [7]. Later studies found that this stimulation
is dose-, time-, and temperature-dependent, and that
neither C1q nor SP-D enhanced DPPC uptake by
macrophages [95]. The degradation of internalized
lipids, however, was not changed in the presence of
SP-A, a ¢nding consistent with earlier studies by
Miles et al. which examined the degradation of lipids
from whole surfactant preparations and ones from
which the major hydrophilic proteins had been ex-
tracted [96].
The study by Wright and Youmans also demon-
strated for the ¢rst time that alveolar macrophages
degrade SP-A in a time- and temperature-dependent
manner, and that this uptake is independent of the
presence of surfactant lipids [95]. These ¢ndings were
con¢rmed in a later study by Bates and Fisher, who
found that rat macrophages degraded SP-A in a
time- and concentration-dependent manner, and
that they degraded human and rat SP-A much
more than bovine SP-A [97]. This degradation was
con¢rmed to be intracellular and independent of sur-
factant lipids [97]. A follow-up to this study demon-
strated that activation of macrophages (both alveolar
and tissue) by overnight culture on tissue culture
plastic in medium containing 10% fetal calf serum
signi¢cantly enhanced the ability of the cells to de-
grade SP-A; overnight culture had no e¡ect on cell
association of SP-A, nor did it a¡ect the degradation
of phospholipids [98].
Many studies have looked at the e¡ect of SP-A on
the binding and phagocytosis of foreign particles,
including a wide variety of pathogenic organisms.
Initial studies compared the e¡ects of SP-A to the
known properties of C1q, a serum homologue in-
volved in the initiation of the complement cascade
and the activation of phagocyte response to IgG. In
these studies, it was demonstrated that SP-A enhan-
ces FcR- and CR1-mediated phagocytosis by periph-
eral blood monocytes and monocyte-derived macro-
phages in a manner similar, though not identical, to
stimulation by C1q [99]. In this study, cells were
adhered to wells coated with C1q, SP-A, or, as a
control, transferrin (see Fig. 3). Monocytes adhered
to SP-A or C1q phagocytosed signi¢cantly more
IgG- or C4b-opsonized sheep erythrocytes than did
the control cells [99].
Van Iwaarden and colleagues examined the e¡ect
of SP-A on the binding of serum-opsonized S. aureus
(SAE) to alveolar macrophages [86]. In an assay that
measured the association of 3H-labeled SAE with
alveolar macrophages, it was demonstrated that pre-
incubation of the macrophages with either SP-A or
surfactant signi¢cantly enhances the association of
serum-opsonized SAE with the cells. The results
seen with SP-A were dose-dependent, and not seen
when SAE were not ¢rst preopsonized with serum or
when bacteria (and not cells) were preincubated with
SP-A [86]. These results did not support the ¢ndings
of several earlier studies, which showed that the ad-
dition of alveolar lining material signi¢cantly en-
hanced the inactivation of S. aureus with alveolar
macrophages [100], and that human lung lavage en-
hanced the association of S. aureus with alveolar
macrophages [101].
Many subsequent studies tested whether SP-A
could act as an opsonin for phagocytosis (Fig. 3A).
In studies using a variety of methods, most of which
did not distinguish bound from internalized patho-
gens, SP-A was shown to enhance the phagocytosis
of herpes simplex 1 with rat alveolar macrophages
[102], and the association of logarithmically growing
Escherichia coli, both log- and stationary-phase Pseu-
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domonas aeruginosa, and log-phase S. aureus with rat
alveolar macrophages [103], S. aureus but not pneu-
mococci with both rabbit alveolar macrophages and
human monocyte-derived macrophages [104], type A
but not type B Haemophilus in£uenzae with rabbit
alveolar macrophages [105], S. aureus with human
peripheral blood monocytes [69], rough but not
smooth E. coli with alveolar macrophages [106],
and Pneumocystis carinii with rat alveolar macro-
phages [107]. While these studies created some con-
troversy about the nature of SP-A-pathogen interac-
tions, and the precise types of pathogens which are
opsonized by SP-A, all of them demonstrated the
ability of SP-A alone to directly stimulate the asso-
ciation of pathogens with phagocytic cells.
Two more recent studies have used methods that
e¡ectively distinguish between intracellular and ex-
tracellular bacteria, in order to separate cell associ-
ated bacteria from internalized ones; both of these
studies have con¢rmed the ability of SP-A to directly
stimulate the phagocytosis of pathogens by macro-
phages. In the ¢rst of these studies, trypan blue dye
was used to quench the £uorescence of extracellular
bacteria, using a method developed by Newman et
al. [108] to study the phagocytosis of yeasts by alveo-
lar macrophages. In this study, it was demonstrated
that SP-A stimulates the phagocytosis of H. in£uen-
zae, Group A Streptococcus, and S. pneumoniae by
alveolar macrophages; this stimulation was shown to
be concentration-dependent, and antibodies to SP-A
blocked the stimulation of phagocytosis by bron-
choalveolar lavage £uid [109]. The later study used
electron microscopy to measure phagocytosis, and
showed that SP-A enhances the uptake of Bacillus
Calmette-Gue¤rin (BCG) by bone marrow-derived
macrophages [110].
The stimulation of phagocytosis by SP-A is gener-
ally seen as an enhancement of pulmonary host de-
fense. In two studies, another perspective on this
interaction has emerged. Two di¡erent studies have
shown that SP-A enhances the association of Myco-
bacterium tuberculosis (MTB) with alveolar macro-
phages [111] and monocyte-derived macrophages
[35]; binding of MTB to cells is an important ¢rst
step in the tuberculosis infection, as MTB lives and
divides intracellularly. Downing and colleagues ex-
amined factors in the lavage of patients with human
immunode¢ciency virus (HIV) infections which in-
creased cell association of MTB; SP-A was identi¢ed
as the factor which enhanced MTB association 3-fold
over control groups, and was postulated to be an
important contributor to the development of tuber-
culosis during the progression of HIV infection [111].
In the study by Gaynor and colleagues, SP-A in-
creased the association of MTB with monocyte-de-
rived macrophages; this association was con¢rmed
Fig. 3. E¡ect of various methods of presenting SP-A to cells on phagocyte function. SP-A presented to phagocytes in di¡erent states
can lead to the stimulation or inhibition of various macrophage functions. (A) SP-A bound to bacteria or viruses can serve as an op-
sonin, directly mediating the interaction between pathogens and cells, and stimulating the phagocytosis of the pathogens. (B) Cells ad-
hered to an SP-A-coated surface are activated to produce reactive oxygen species, as well as to phagocytose particles opsonized with
molecules such as IgG, which mediates the interaction of particles with cells via the Fc receptor. (C) Cells adhered to an SP-A-coated
surface also lack a response to soluble SP-A, presumably because SP-A binding cell surface receptors are clustered on the basal sur-
face of the cell and are therefore unavailable to interact with SP-A in solution. These cells do not respond to SP-A presented as an
opsonin for bacterial phagocytosis.
BBADIS 61775 30-10-98
M.J. Tino, J.R. Wright / Biochimica et Biophysica Acta 1408 (1998) 241^263258
to lead to increased phagocytosis by electron micro-
scopy, and was inhibited by both mannan and anti-
bodies to the anti-mannose receptor [35].
Several studies of SP-A-mediated phagocytosis
have examined the cell surface receptors likely to
be involved in this stimulation. Receptor clustering
studies have led to some controversy about the exact
receptors involved in the stimulation of phagocytosis
by SP-A; adherence of cells to a ligand-coated sur-
face has been shown in some systems to cluster re-
ceptors for that ligand on the basal surface of the
cells, making them unavailable to interact with
soluble or particle-bound ligand (Fig. 3) [112]. In
the study by Geertsma and colleagues [69], peripheral
blood monocytes were adhered to surfaces coated
with a high concentration of C1q; this coating
eliminated the SP-A mediated enhancement of S.
aureus association with cells. These results were in-
terpreted as supporting the hypothesis that C1q re-
ceptors mediate the stimulation of phagocytes by
SP-A.
In a later study, however, we demonstrated that
while monocytes adhered to C1q-coated surfaces
lose responsiveness to SP-A, alveolar macrophages
retain their responsiveness to SP-A on these surfaces;
additionally, it was shown that SP-A does not stim-
ulate the phagocytosis of H. in£uenzae in alveolar
macrophages adhered to SP-A-coated surfaces, and
that adherence to C1q-coated surfaces signi¢cantly
inhibits baseline phagocytosis of bacteria in both
cell types [109]. Recently, Weikert and colleagues
have shown that antibodies to SPR210, an SP-A
binding protein expressed on many cell types, block
SP-A enhancement of BCG uptake by bone marrow-
derived macrophages; this is the ¢rst direct demon-
stration of the involvement of a speci¢c protein in
SP-A stimulation of a phagocyte [110]. This study
also showed that the macrophage mannose receptor
was not responsible for this stimulation, as studies on
MTB had postulated.
Further studies are needed to determine the specif-
ic receptor(s) on alveolar macrophages necessary for
SP-A interaction and stimulation. The nature of the
SP-A ^ soluble, pathogen-bound, surface-bound and/
or lipid-bound ^ may determine the precise set of
processes stimulated. Additionally, the cell types
with which future studies are conducted may prove
essential; di¡erences in cellular responsiveness to SP-
A have been shown among phagocytes (see Table 1).
The cellular distribution of receptors known to bind
SP-A does not match the cellular speci¢city of stim-
ulation, the strong possibility exists that several re-
ceptors are responsible for the various interactions of
SP-A with phagocytic cells.
Table 1
E¡ects of SP-A on the host defense functions of mononuclear phagocytes
Function Alveolar macrophages Peripheral blood monocytes or
monocytic cell lines
SP-A binding Speci¢c Non-saturable
Saturable Bind and internalize SP-A-gold
High-a⁄nity C1q-R (U937)
Bind and internalize SP-A-gold SPR-210 (U937)
SPR-210
Stimulates the phagocytosis or association of
non-opsonized organisms
+ +
Activation ligand for phagocytosis via FcR and CR1 n.d. +
Stimulates chemotaxis + 3
Stimulates actin polymerization + 3
Increases intracellular calcium and IP3 + n.d.
Stimulates protein tyrosine phosphorylation + 3
A¡ects the production of: TNF-K IL-1L
IL-1L IL-6
Reactive O2 species
Nitric oxide
Increases the expression of: iNOS CD14, CD54, CD11b (THP1)
+, functions stimulated by SP-A; 3, functions not a¡ected by SP-A; n.d., not done.
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6. Future perspectives
In summary, numerous studies employing a wide
variety of techniques have provided evidence that
SP-A can interact with and a¡ect the functions of
alveolar epithelial and immune cells. These studies
are all consistent with the possibility that both type
II cells and immune cells express speci¢c receptors
for SP-A. Although several SP-A binding proteins
on type II cells and macrophages have been identi-
¢ed, little is known about the putative receptors and
how they may transduce SP-A mediated to the cells.
Important future areas will be the cloning and ex-
pression of these receptors and elucidation of the
mechanism by which they interact with SP-A and
regulate cell function.
In vitro studies show that SP-A appears to be in-
volved in regulating surfactant metabolism (Fig. 1).
These studies have been the basis for a model in
which SP-A regulates surfactant pool size. In this
model, when surfactant is in excess in the extracellu-
lar space, SP-A enhances lipid uptake by either type
II cells, where it can be recycled or degraded and
reused to synthesize new surfactant, or by macro-
phages, which actively degrade both lipid and SP-
A. Further secretion is inhibited by the interaction
of SP-A with the type II cells. Little is known about
the mechanisms by which SP-A exerts these e¡ects,
although recent studies have identi¢ed potential re-
ceptors and SP-A binding domains involved in this
process. Although these in vitro studies provide com-
pelling evidenced that SP-A is involved in regulating
surfactant metabolism, mice in which SP-A has been
deleted by homologous recombination were found to
have relatively small perturbations to their extracel-
lular surfactant pool sizes. One possible explanation
for the observation that the pool size perturbations
were smaller than might have been expected is that
alternative compensatory mechanisms may regulate
surfactant pool size in the absence of SP-A. These
compensatory mechanisms could possibly be over-
whelmed in scenarios in which the animals are
stressed by exercise, in£ammation, or infection.
The involvement of SP-A in regulating immune
cell function is supported by both in vitro studies
and in vivo studies. In general, the in vitro studies
have shown that SP-A enhances the e¡ects of im-
mune cells such as phagocytosis and bacterial killing
as well as chemotaxis. There are some con£icting
reports in the literature about the role of SP-A in
regulating cytokine and free radical production. Pos-
sible explanations for these con£icts include di¡erent
methods of preparation of SP-A and the possibility
that the ‘puri¢ed’ SP-A may be contaminated with
endotoxin and immunoglobulins among other fac-
tors. Alternatively, speci¢c immune cells or cell lines
may have unique responses to SP-A. In vivo studies
using mice in which the SP-A gene has been ablated
support the idea that SP-A functions in host defense;
these mice are more susceptible to pulmonary infec-
tions than are wild type mice. Although the studies
with the knock-out mice have provided con¢rmation
for the in vitro studies, there are still many unan-
swered questions about the role of SP-A in host de-
fense. For example, the relative roles of di¡erent im-
mune cells, such as macrophages, monocytes,
neutrophils and T-cells, are not known. The possible
interaction of SP-A with other immune proteins such
as SP-D and those of the adaptive immune system
has not been thoroughly investigated.
Another important unanswered question is what
regulates the relative contribution of SP-A to regu-
lating type II cell or immune cell function. SP-A as
isolated from lung lavage is largely bound to lipid.
Therefore, it seems important to elucidate the e¡ects
of lipids on SP-A mediated functions. However, since
SP-A is also synthesized by the airway Clara cell, it
seems likely that SP-A may be secreted without lipid
from this cell type and then become lipid associated
during the lavage procedure. The e¡ects of these po-
tentially di¡erent forms of SP-A have not been in-
vestigated. Finally, little is known about the func-
tions of SP-A in the injured or infected lung and
the factors that regulate the expression of SP-A
under such conditions.
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